Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
Primary adrenal insufficiency is a serious, life-threatening condition in which the adrenal glands fail to produce sufficient levels of essential hormones such as cortisol, a key regulator of the body's stress response. The current standard of care involves daily hormone replacement therapy, which does not fully replicate the body's natural circadian hormone rhythms and is associated with significant drug-related side effects. This can leave patients with a poor quality of life and at risk of ongoing health challenges, including potentially fatal adrenal crises.
Aspect's adrenal BTTs were developed using the company's proprietary full-stack tissue therapeutic platform, which combines AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials.
In preclinical studies, adrenal BTTs containing human adrenal cells were implanted into adrenalectomized mice. These BTTs produced cortisol in response to adrenocorticotropic hormone (ACTH) stimulation—which is normally secreted from the brain—and followed the animals' natural circadian fluctuations in hormone levels. When exposed to high levels of injected ACTH, these mice demonstrated rapid increases in circulating cortisol, confirming that the adrenal BTTs were functionally responsive. In contrast, control animals receiving cell-free implants showed no significant cortisol levels and did not respond to ACTH stimulation. Importantly, adrenal BTTs remained functional in vivo throughout the study period of over six months and improved animal survival.
'Our research shows that Aspect's adrenal BTTs successfully replicate healthy human adrenal gland function by releasing cortisol in a pattern that follows the natural daily rhythms of hormone release and by responding appropriately to a stimulus that mimics a stress response,' said Sam Wadsworth, PhD, Chief Scientific Officer at Aspect Biosystems. 'These results demonstrate that our off-the-shelf, implantable cell therapy can work in harmony with the body's physiology and has real potential to serve as a functional cure for primary adrenal insufficiency."
'At Aspect, we're making breakthrough progress with our Bioprinted Tissue Therapeutics platform to restore complex biological functions across a range of serious endocrine and metabolic diseases,' said Tamer Mohamed, Chief Executive Officer of Aspect Biosystems. 'This latest advance in primary adrenal insufficiency, a rare and life-threatening condition with limited treatment options, showcases the potential of a bioengineered cell therapy to recreate natural hormone function and deliver a truly disease-modifying solution. This reflects our mission to develop regenerative medicines capable of achieving functional cures for patients with serious and underserved diseases.'
About ENDO
Hosted by the Endocrine Society, ENDO is the leading global meeting on endocrinology research and clinical care. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. Learn more at www.endocrine.org/.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform how we treat some of the most elusive diseases. Aspect's BTTs are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of BTTs across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit www.aspectbiosystems.com and follow on LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
BerryDunn Showcases Thought Leadership and Expertise at 2025 MESC Conference
PORTLAND, Maine--(BUSINESS WIRE)--BerryDunn, a full-service accounting, tax, and consulting firm, will return for the 25th year to the Medicaid Enterprise Systems Conference (MESC), taking place August 11 – 14 in Milwaukee, WI. The firm is a leading voice in Medicaid and other Health and Human Services (HHS) policy, program excellence, and healthcare data analytics, with decades of hands-on experience supporting states and territories. The MESC brings together territorial, state, federal, and private-sector leaders to discuss and collaborate on Medicaid and other HHS systems and the policies that affect them. Hot topics at MESC 2025 include systems optimization, healthcare IT strategy, and a strong emphasis on modernization, interoperability, and health equity. 'The urgency for the healthcare community to prioritize the well-being of those they serve—while modernizing systems, ensuring compliance, and driving innovation—has never been greater,' says Zachary Rioux, Principal at BerryDunn. 'Our team is deeply committed to helping clients build future-ready solutions that are both strategic and sustainable. We've supported agencies in preparing for and responding to major federal legislation like the One Big Beautiful Bill Act (OBBBA), and we continue to guide clients through the evolving policy landscape.' BerryDunn's involvement with industry associations, governance boards, and conferences enables the consulting team to anticipate and help clients respond to developments like the recent State Health Officials (SHO) letter #25003 and upcoming changes to the Medicaid Information Technology Architecture (MITA). MESC is a powerful gathering of ideas, experience, and purpose—and BerryDunn is proud to be part of a community that's driving meaningful change in healthcare. Several BerryDunn professionals will play a leading role in this year's conference presentations, including: Alexandra Nardo and Robert Morey will speak during a session titled 'Building the Foundation for AI: Puerto Rico's AI Readiness Roadmap.' The session explores the Puerto Rico Medicaid Program's assessment, planning process, and roadmap in support of the agency's AI considerations. Delivering purposeful results through partnership, Amber Davis, a Manager in BerryDunn's Medicaid Practice Group, will moderate a session on 'Advancing Medicaid Innovation through the CMS Leverage & Reuse Initiative.' This session will explore how states and territories are collaborating to drive efficiency, reduce costs, and accelerate innovation in Medicaid technology. Partnering with CMS and the leadership team at the Puerto Rico Medicaid Program (PRMP), Nikki Welch, Manager at BerryDunn, will present 'Leveraging Organizational Change Management (OCM) Maturity Results to Enhance Medicaid Outcomes.' This session highlights PRMP's journey to integrate OCM practices across Medicaid Enterprise Systems (MES) and how the use of BerryDunn's OCM Maturity Assessment framework has provided measurable insights that directly support program success. 'Our team members gain valuable perspective by being actively engaged in Medicaid IT and policy planning at the national and state levels,' says Ed Daranyi, BerryDunn Principal and leader of the firm's Medicaid Practice Group. 'We provide those insights and deep industry knowledge to clients across the country, supporting innovation in client solutions.' As BerryDunn celebrates 25 years at MESC, the firm remains committed to helping agencies navigate complexity with clarity, purpose, and innovation. With deep expertise in policy, technology, and program excellence, BerryDunn continues to lead with insight and impact. About BerryDunn BerryDunn is the brand name under which Berry, Dunn, McNeil & Parker, LLC and BDMP Assurance, LLP, independently owned entities, provide services. Since 1974, BerryDunn has helped businesses, nonprofits, and government agencies throughout the US and its territories solve their greatest challenges. The firm's tax, advisory, and consulting services are provided by Berry, Dunn, McNeil & Parker, LLC, and its attest services are provided by BDMP Assurance, LLP, a licensed CPA firm. BerryDunn is a client-centered, people-first professional services firm with a mission to empower the meaningful growth of our people, clients, and communities. Led by CEO Sarah Belliveau, the firm has been recognized for its efforts in creating a diverse and inclusive workplace culture, and for its focus on learning, development, and well-being. Learn more at
Business Wire
2 days ago
- Business Wire
Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the UBS Precision Medicine Frontiers Summit taking place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, August 13-14, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be available for one-on-one meetings throughout the day on Thursday, August 14, 2025, and Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel on the same day from 8:15 – 8:50 AM Pacific Daylight Time. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X.
Business Wire
2 days ago
- Business Wire
NHC Reports Second Quarter 2025 Earnings
MURFREESBORO, Tenn.--(BUSINESS WIRE)-- National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter of 2025 compared to the second quarter of 2024 was due to an 9.6% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Management, Inc. ('White Oak'). For the quarter ended June 30, 2025, the reported GAAP net income attributable to NHC was $23,722,000 compared to $26,844,000 for the same period in 2024. Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended June 30, 2025 was $25,710,000 compared to $15,612,000 for the same period in 2024, an increase of 64.7% (*). The GAAP diluted earnings per share were $1.52 and $1.73 for the quarters ending June 30, 2025 and 2024, respectively. Adjusted diluted earnings per share were $1.65 and $1.00 for the quarters ending June 30, 2025 and 2024, respectively (*). (*) - See the tables below that provide a reconciliation of GAAP to non-GAAP items. Expand About NHC As of August 1, 2025, NHC affiliates operate for themselves and third parties 80 skilled nursing facilities with 10,329 beds. NHC affiliates also operate 26 assisted living communities with 1,413 units, nine independent living communities with 777 units, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies. NHC's other services include Alzheimer's and memory care units, pharmacy services, a rehabilitation services company, and providing management and accounting services to third party post-acute operators. Other information about the company can be found on our web site at Non-GAAP Financial Presentation The Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Forward-Looking Statements Statements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q, and 10-K. All forward-looking statements represent NHC's best judgment as of the date of this release. Selected Operating Statistics Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Skilled Nursing Per Diems: Medicare $ 614.85 $ 577.71 $ 613.47 $ 579.81 Managed Care 486.17 447.96 489.30 459.48 Medicaid 286.43 264.49 284.07 264.88 Private Pay and Other 341.34 312.91 339.24 310.31 Average Skilled Nursing Per Diem $ 361.42 $ 338.86 $ 360.78 (1) $ 341.21 (1) Skilled Nursing Patient Days: Medicare 83,615 74,602 169,869 155,758 Managed Care 83,015 62,957 166,661 128,388 Medicaid 368,687 279,504 732,329 561,325 Private Pay and Other 194,202 150,234 378,796 307,677 Total Skilled Nursing Patient Days 729,519 567,297 1,447,655 (1) 1,153,148 (1) (1) NHC exited three skilled nursing facilities in Missouri on March 1, 2024. For the six months ended June 30, 2024, the exited Missouri skilled nursing facilities had an average skilled nursing per diem of $275.64 and 20,267 patient days. The tables below provide reconciliations of GAAP to non-GAAP items (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Net income attributable to National Healthcare Corporation $ 23,722 $ 26,844 $ 55,927 $ 53,057 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 5,061 (9,124 ) (5,921 ) (23,523 ) Operating losses for newly-opened operations not at full capacity - 20 - 20 Gain on sale of property and equipment (3,606 ) - (3,606 ) - Gain on sale of unconsolidated company - - - (1,024 ) Stock-based compensation expense 1,232 1,176 2,260 1,969 Acquisition-related expenses - 2,194 - 2,194 Employee retention credit - (9,445 ) - (9,445 ) Income tax provision/(benefit) on non-GAAP adjustments (699 ) 3,947 1,889 7,750 Non-GAAP Net income $ 25,710 $ 15,612 $ 50,549 $ 30,998 GAAP diluted earnings per share $ 1.52 $ 1.73 $ 3.59 $ 3.42 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 0.32 (0.59 ) (0.38 ) (1.51 ) Gain on sale of property and equipment (0.23 ) - (0.23 ) - Gain on sale of unconsolidated company - - - (0.07 ) Stock-based compensation expense 0.08 0.08 0.14 0.13 Acquisition-related expenses - 0.14 - 0.14 Employee retention credit - (0.61 ) - (0.61 ) Income tax provision/(benefit) on non-GAAP adjustments (0.04 ) 0.25 0.12 0.50 Non-GAAP diluted earnings per share $ 1.65 $ 1.00 $ 3.24 $ 2.00 Expand
